Literature DB >> 22011441

Regulation of cytochrome P450 4F11 by nuclear transcription factor-κB.

Jordan C Bell1, Henry W Strobel.   

Abstract

Although the mechanisms that regulate CYP4F genes have been and are currently being studied in a number of laboratories, the specific mechanisms for the regulation of these genes are not yet fully understood. This study shows that nuclear factor κB of the light-chain-enhancer in activated B cells (NF-κB) can inhibit CYP4F11 expression in human liver carcinoma cell line (HepG2) as summarized below. Tumor necrosis factor-α (TNF-α), a proinflammatory cytokine, has been shown to activate NF-κB signaling while also activating the c-Jun NH(2)-terminal kinase (JNK) signaling pathway. Other studies have reported that JNK signaling can up-regulate CYP4F11 expression. The results of this study demonstrate that in the presence of TNF-α and the specific NF-κB translocation inhibitor N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide (IMD-0354), there is a greater increase in CYP4F11 expression than that elicited by TNF-α alone, indicating that NF-κB plays an inhibitory role. Moreover, NF-κB stimulation by overexpression of mitogen-activated protein kinase kinase kinase inhibited CYP4F11 promoter expression. CYP4F11 promoter inhibition can also be rescued in the presence of TNF-α when p65, a NF-κB protein, is knocked down. Thus, NF-κB signaling pathways negatively regulate the CYP4F11 gene.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22011441      PMCID: PMC3250053          DOI: 10.1124/dmd.111.041178

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  19 in total

1.  Transcriptional and post-transcriptional suppression of P450IIC11 and P450IIC12 by inflammation.

Authors:  K Wright; E T Morgan
Journal:  FEBS Lett       Date:  1990-10-01       Impact factor: 4.124

2.  Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling.

Authors:  E De Smaele; F Zazzeroni; S Papa; D U Nguyen; R Jin; J Jones; R Cong; G Franzoso
Journal:  Nature       Date:  2001-11-15       Impact factor: 49.962

3.  Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide.

Authors:  S Ke; A B Rabson; J F Germino; M A Gallo; Y Tian
Journal:  J Biol Chem       Date:  2001-07-24       Impact factor: 5.157

4.  Depression of liver drug metabolism and increase in plasma fibrinogen by interleukin 1 and tumor necrosis factor: a comparison with lymphotoxin and interferon.

Authors:  R Bertini; M Bianchi; P Villa; P Ghezzi
Journal:  Int J Immunopharmacol       Date:  1988

5.  Suppression of constitutive cytochrome P-450 gene expression in livers of rats undergoing an acute phase response to endotoxin.

Authors:  E T Morgan
Journal:  Mol Pharmacol       Date:  1989-11       Impact factor: 4.436

6.  Interleukin-1 (IL-1) depresses cytochrome P450 levels and activities in mice.

Authors:  S I Shedlofsky; A T Swim; J M Robinson; V S Gallicchio; D A Cohen; C J McClain
Journal:  Life Sci       Date:  1987-06-15       Impact factor: 5.037

7.  Role of interleukin-1 in the depression of liver drug metabolism by endotoxin.

Authors:  P Ghezzi; B Saccardo; P Villa; V Rossi; M Bianchi; C A Dinarello
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

8.  Expression and characterization of human cytochrome P450 4F11: Putative role in the metabolism of therapeutic drugs and eicosanoids.

Authors:  Auinash Kalsotra; Cheri M Turman; Yasushi Kikuta; Henry W Strobel
Journal:  Toxicol Appl Pharmacol       Date:  2004-09-15       Impact factor: 4.219

9.  A JNK-dependent pathway is required for TNFalpha-induced apoptosis.

Authors:  Yibin Deng; Xiaoyang Ren; Lin Yang; Yahong Lin; Xiangwei Wu
Journal:  Cell       Date:  2003-10-03       Impact factor: 41.582

10.  Inflammatory prompts produce isoform-specific changes in the expression of leukotriene B(4) omega-hydroxylases in rat liver and kidney.

Authors:  Auinash Kalsotra; Xiaoming Cui; Leposava Antonovic; Aaron M Robida; Edward T Morgan; Henry W Strobel
Journal:  FEBS Lett       Date:  2003-12-04       Impact factor: 4.124

View more
  4 in total

1.  DNA methylation is globally disrupted and associated with expression changes in chronic obstructive pulmonary disease small airways.

Authors:  Emily A Vucic; Raj Chari; Kelsie L Thu; Ian M Wilson; Allison M Cotton; Jennifer Y Kennett; May Zhang; Kim M Lonergan; Katrina Steiling; Carolyn J Brown; Annette McWilliams; Keishi Ohtani; Marc E Lenburg; Don D Sin; Avrum Spira; Calum E Macaulay; Stephen Lam; Wan L Lam
Journal:  Am J Respir Cell Mol Biol       Date:  2014-05       Impact factor: 6.914

Review 2.  CYP4 enzymes as potential drug targets: focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid ω-hydroxylase activities.

Authors:  Katheryne Z Edson; Allan E Rettie
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

3.  Alpha-ketoglutarate suppresses the NF-κB-mediated inflammatory pathway and enhances the PXR-regulated detoxification pathway.

Authors:  Liuqin He; Huan Li; Niu Huang; Xihong Zhou; Junquan Tian; Tiejun Li; Jing Wu; Yanan Tian; Yulong Yin; Kang Yao
Journal:  Oncotarget       Date:  2017-04-06

4.  Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients.

Authors:  Cong Wang; Fang Chen; Yichen Liu; Qingqing Xu; Liang Guo; Xiaoqing Zhang; Yunfeng Ruan; Ye Shi; Lu Shen; Mo Li; Huihui Du; Xiaofang Sun; Jingsong Ma; Lin He; Shengying Qin
Journal:  Front Pharmacol       Date:  2018-04-11       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.